Gilead Sciences Inc.
Gilead Sciences Reports Q4 and Full Year 2023 Financial Results
Summary
Gilead Sciences, Inc. announced its financial results for Q4 and full year 2023 on February 6, 2024. Total Q4 revenue decreased by 4% to $7.1 billion, driven by lower Veklury and HIV sales, partially offset by higher Oncology sales. Diluted EPS decreased to $1.14 in Q4 2023 from $1.30 in Q4 2022. Full-year 2023 revenue decreased by 1% to $27.1 billion, with Veklury sales down 44% and HIV and Oncology sales up 6% and 37% respectively. Full-year diluted EPS increased to $4.50 from $3.64 in 2022. The company also provided guidance for 2024, anticipating total product sales between $27.1 billion and $27.5 billion.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement